Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalized medicine in lipid-modifying therapy.

Personalized medicine - 1 Mar 2021

Tomlinson Brian, Lin Chen-Hsiu, Chan Paul, Lam Christopher Wk

Abstract excerpt

The choice of lipid-modifying treatment is largely based on the absolute level of cardiovascular risk and baseline lipid profile. Statins are the first-line treatment for most patients requiring reduction of low-density-lipoprotein cholesterol (LDL-C) and ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors can be added to reach LDL-C targets. Statins have some adverse effects that are somewhat...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholesterol, LDL
Share to Comorbidity
Share to Dyslipidemias

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatty Acids, Omega-3

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hypolipidemic Agents

Share to Lipoprotein(a)

Share to Proprotein Convertase 9

Source

Identifiers

PMID: 33565320
DOI: 10.2217/pme-2020-0110

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized medicine in lipid-modifying therapy.PMID 33565320Read ↗

Gene-based therapy in lipid management: the winding road from promise to practiceSemantic proximity Read ↗

Statins personalized.Semantic proximity Read ↗

Pharmacogenomics, lipid disorders, and treatment options.Semantic proximity Read ↗

Genetics and personalized medicine--a role in statin therapy?Semantic proximity Read ↗

[PERSONALIZED APPROACH TO LIPID-LOWERING THERAPY].Semantic proximity Read ↗

Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.Semantic proximity Read ↗

Personalized medicine in nonalcoholic fatty liver disease.Semantic proximity Read ↗

From physiopathology to treatment of familial hypercholesterolemia: Existing and emerging pharmacotherapies.Semantic proximity Read ↗

A new dawn for managing dyslipidemias: The era of rna-based therapiesSemantic proximity Read ↗

RNA Silencing in the Management of DyslipidemiasSemantic proximity Read ↗

Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease.Semantic proximity Read ↗

Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.